CytoSorbents Reports 10% Revenue Growth and Improved Gross Margins in Q3 2025
Reuters
Nov 14
CytoSorbents Reports 10% Revenue Growth and Improved Gross Margins in Q3 2025
CytoSorbents Corporation reported third quarter 2025 financial results, announcing revenue of $9.5 million, a 10% increase compared to $8.6 million in the third quarter of 2024. On a constant currency basis, revenue grew by 4%. The company noted record performance in distributor territories and near-record performance in direct sales outside Germany. Gross margin for the quarter was 70%, up from 61% in the same period last year, attributed to the resolution of prior production and manufacturing issues. CytoSorbents also amended its credit agreement with Avenue Capital Group, securing an additional $2.5 million in cash and extending the interest-only period through December 31, 2026, with the potential for further extension and funding contingent on regulatory approval. The company implemented a workforce and cost reduction program aimed at achieving cash-flow breakeven by the first quarter of 2026. Additionally, CytoSorbents submitted a DrugSorb-ATR De Novo pre-submission package to the FDA, with a regulatory decision anticipated by mid-2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY24252) on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.